• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 感染和 COVID-19 康复过程中抗 SARS-CoV-2 抗体的动态变化。

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.

机构信息

The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing, China.

Center for Global Health, School of Public Health, Nanjing Medical University, 211166, Nanjing, Jiangsu, China.

出版信息

Nat Commun. 2020 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y.

DOI:10.1038/s41467-020-19943-y
PMID:33247152
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7699636/
Abstract

Deciphering the dynamic changes in antibodies against SARS-CoV-2 is essential for understanding the immune response in COVID-19 patients. Here we analyze the laboratory findings of 1,850 patients to describe the dynamic changes of the total antibody, spike protein (S)-, receptor-binding domain (RBD)-, and nucleoprotein (N)-specific immunoglobulin M (IgM) and G (IgG) levels during SARS-CoV-2 infection and recovery. The generation of S-, RBD-, and N-specific IgG occurs one week later in patients with severe/critical COVID-19 compared to patients with mild/moderate disease, while S- and RBD-specific IgG levels are 1.5-fold higher in severe/critical patients during hospitalization. The RBD-specific IgG levels are 4-fold higher in older patients than in younger patients during hospitalization. In addition, the S- and RBD-specific IgG levels are 2-fold higher in the recovered patients who are SARS-CoV-2 RNA negative than those who are RNA positive. Lower S-, RBD-, and N-specific IgG levels are associated with a lower lymphocyte percentage, higher neutrophil percentage, and a longer duration of viral shedding. Patients with low antibody levels on discharge might thereby have a high chance of being tested positive for SARS-CoV-2 RNA after recovery. Our study provides important information for COVID-19 diagnosis, treatment, and vaccine development.

摘要

解析针对 SARS-CoV-2 的抗体的动态变化对于理解 COVID-19 患者的免疫反应至关重要。在这里,我们分析了 1850 名患者的实验室检查结果,以描述 SARS-CoV-2 感染和康复期间总抗体、刺突蛋白(S)、受体结合域(RBD)和核衣壳蛋白(N)特异性免疫球蛋白 M(IgM)和 G(IgG)水平的动态变化。与轻症/中度疾病患者相比,重症/危重症 COVID-19 患者的 S-、RBD-和 N-特异性 IgG 的产生滞后一周,而住院期间重症/危重症患者的 S-和 RBD-特异性 IgG 水平高 1.5 倍。住院期间,老年患者的 RBD 特异性 IgG 水平比年轻患者高 4 倍。此外,在 SARS-CoV-2 RNA 阴性的康复患者中,S-和 RBD-特异性 IgG 水平是 RNA 阳性患者的 2 倍。较低的 S-、RBD-和 N-特异性 IgG 水平与较低的淋巴细胞百分比、较高的中性粒细胞百分比和较长的病毒脱落持续时间相关。出院时抗体水平较低的患者在康复后可能有很高的机会检测到 SARS-CoV-2 RNA 阳性。我们的研究为 COVID-19 的诊断、治疗和疫苗开发提供了重要信息。

相似文献

1
Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19.SARS-CoV-2 感染和 COVID-19 康复过程中抗 SARS-CoV-2 抗体的动态变化。
Nat Commun. 2020 Nov 27;11(1):6044. doi: 10.1038/s41467-020-19943-y.
2
Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).儿童多系统炎症综合征(MIS-C)中 SARS-CoV-2 血清学的定量分析。
Pediatrics. 2020 Dec;146(6). doi: 10.1542/peds.2020-018242. Epub 2020 Sep 2.
3
Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.中国北京一家三级甲等医院中新冠病毒肺炎患者抗体反应的纵向分析
Front Immunol. 2021 Mar 15;12:614436. doi: 10.3389/fimmu.2021.614436. eCollection 2021.
4
Validation of a new automated chemiluminescent anti-SARS-CoV-2 IgM and IgG antibody assay system detecting both N and S proteins in Japan.日本一种新型自动化化学发光抗SARS-CoV-2 IgM和IgG抗体检测系统的验证,该系统可同时检测N蛋白和S蛋白。
PLoS One. 2021 Mar 4;16(3):e0247711. doi: 10.1371/journal.pone.0247711. eCollection 2021.
5
Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence.在 COVID-19 和恢复期,针对 SARS-CoV-2 刺突和核衣壳蛋白快速产生持久的 B 细胞记忆。
Sci Immunol. 2020 Dec 22;5(54). doi: 10.1126/sciimmunol.abf8891.
6
Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.新冠肺炎患者血清中数月来持续存在对 SARS-CoV-2 的中和活性。
Viruses. 2020 Nov 27;12(12):1357. doi: 10.3390/v12121357.
7
Dynamic Changes of Antibodies to SARS-CoV-2 in COVID-19 Patients at Early Stage of Outbreak.COVID-19 患者在疫情早期对 SARS-CoV-2 抗体的动态变化。
Virol Sin. 2020 Dec;35(6):744-751. doi: 10.1007/s12250-020-00268-5. Epub 2020 Jul 27.
8
Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.评估 SARS-CoV-2 捕获 IgM 抗体检测试剂盒在恢复期血清中的应用。
Microbiol Spectr. 2021 Oct 31;9(2):e0045821. doi: 10.1128/Spectrum.00458-21. Epub 2021 Sep 8.
9
A Combination of N and S Antigens With IgA and IgG Measurement Strengthens the Accuracy of SARS-CoV-2 Serodiagnostics.N 抗原和 S 抗原与 IgA 和 IgG 联合检测可提高 SARS-CoV-2 血清学诊断的准确性。
J Infect Dis. 2021 Jul 15;224(2):218-228. doi: 10.1093/infdis/jiab222.
10
Low Innate Immunity and Lagged Adaptive Immune Response in the Re-Tested Viral RNA Positivity of a COVID-19 Patient.COVID-19 患者再次检测到病毒 RNA 阳性时存在低固有免疫和滞后适应性免疫反应。
Front Immunol. 2021 Jul 1;12:664619. doi: 10.3389/fimmu.2021.664619. eCollection 2021.

引用本文的文献

1
The roles of macrophages and monocytes in COVID-19 Severe Respiratory Syndrome.巨噬细胞和单核细胞在新型冠状病毒肺炎严重呼吸综合征中的作用。
Cell Insight. 2025 May 8;4(4):100250. doi: 10.1016/j.cellin.2025.100250. eCollection 2025 Aug.
2
COVID-19 mRNA vaccine immune response to the addition of osteopathic manipulative treatment with lymphatic pumps: a randomized controlled trial.COVID-19信使核糖核酸疫苗联合淋巴泵整骨手法治疗的免疫反应:一项随机对照试验
Virus Res. 2025 Jul 14;359:199607. doi: 10.1016/j.virusres.2025.199607.
3
Longitudinal analysis of passively and actively acquired SARS-CoV-2 antibodies in infants with repeat newborn screening samples.

本文引用的文献

1
Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.新冠病毒肺炎患者中中和抗体反应的快速产生
Cell Rep Med. 2020 Jun 23;1(3):100040. doi: 10.1016/j.xcrm.2020.100040. Epub 2020 Jun 8.
2
ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques.ChAdOx1 nCoV-19 疫苗可预防恒河猴的 SARS-CoV-2 肺炎。
Nature. 2020 Oct;586(7830):578-582. doi: 10.1038/s41586-020-2608-y. Epub 2020 Jul 30.
3
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.单次接种 Ad26 疫苗可预防恒河猴感染 SARS-CoV-2。
对具有重复新生儿筛查样本的婴儿中被动和主动获得的SARS-CoV-2抗体的纵向分析。
Sci Rep. 2025 Jul 4;15(1):23881. doi: 10.1038/s41598-025-09140-6.
4
Comparative evaluation of in-house ELISA and two commercial serological assays for the detection of antibodies against SARS-CoV-2.用于检测抗SARS-CoV-2抗体的内部酶联免疫吸附测定(ELISA)和两种商业血清学检测方法的比较评估
Sci Rep. 2025 Apr 22;15(1):13853. doi: 10.1038/s41598-025-97050-y.
5
Flow cytometric analysis of the SARS coronavirus 2 antibodies in human plasma.人血浆中严重急性呼吸综合征冠状病毒2抗体的流式细胞术分析
Sci Rep. 2025 Mar 25;15(1):10300. doi: 10.1038/s41598-025-92389-8.
6
Reflections on COVID-19: A Literature Review of SARS-CoV-2 Testing.关于新冠疫情的思考:严重急性呼吸综合征冠状病毒2检测的文献综述
Vaccines (Basel). 2024 Dec 26;13(1):9. doi: 10.3390/vaccines13010009.
7
Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19.抗核衣壳抗体在严重急性呼吸综合征冠状病毒2感染、再感染及冠状病毒病2019急性后遗症中的有害作用
Pathogens. 2024 Dec 15;13(12):1109. doi: 10.3390/pathogens13121109.
8
Temporal Dynamics and (Para)Clinical Factors Associated With (Long) Viral RNA Shedding in COVID-19 Nonhospitalized Individuals - The COVID-HOME Study.新冠居家研究:非住院COVID-19患者病毒RNA长期脱落的时间动态及(准)临床因素
J Med Virol. 2024 Dec;96(12):e70125. doi: 10.1002/jmv.70125.
9
COVID-19 epidemic investigation study of a follow-up cohort of patients with diabetic kidney disease.COVID-19 疫情对糖尿病肾病患者随访队列的影响调查研究。
Front Cell Infect Microbiol. 2024 Aug 20;14:1388260. doi: 10.3389/fcimb.2024.1388260. eCollection 2024.
10
Human E3 ubiquitin ligases: accelerators and brakes for SARS-CoV-2 infection.人类 E3 泛素连接酶:促进和抑制 SARS-CoV-2 感染。
Biochem Soc Trans. 2024 Oct 30;52(5):2009-2021. doi: 10.1042/BST20230324.
Nature. 2020 Oct;586(7830):583-588. doi: 10.1038/s41586-020-2607-z. Epub 2020 Jul 30.
4
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
5
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.通用设计的贝塔冠状病毒疫苗,用于预防 COVID-19、MERS 和 SARS。
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
6
Assessment of patients who tested positive for COVID-19 after recovery.对康复后新冠病毒检测呈阳性的患者进行评估。
Lancet Infect Dis. 2020 Sep;20(9):1004-1005. doi: 10.1016/S1473-3099(20)30433-3. Epub 2020 Jul 6.
7
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.一种中和性人源抗体结合到了 SARS-CoV-2 的刺突蛋白的 N 端结构域。
Science. 2020 Aug 7;369(6504):650-655. doi: 10.1126/science.abc6952. Epub 2020 Jun 22.
8
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.无症状 SARS-CoV-2 感染的临床和免疫学评估。
Nat Med. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6. Epub 2020 Jun 18.
9
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.病毒刺突蛋白的受体结合域是 SARS-CoV-2 患者体内抗体的免疫优势和高度特异性靶标。
Sci Immunol. 2020 Jun 11;5(48). doi: 10.1126/sciimmunol.abc8413.
10
Seroprevalence of immunoglobulin M and G antibodies against SARS-CoV-2 in China.中国 SARS-CoV-2 免疫球蛋白 M 和 G 抗体的血清流行率。
Nat Med. 2020 Aug;26(8):1193-1195. doi: 10.1038/s41591-020-0949-6. Epub 2020 Jun 5.